| scholarly article | Q13442814 |
| P2093 | author name string | Janice Graham | |
| P2860 | cites work | Wakefield's article linking MMR vaccine and autism was fraudulent | Q22242079 |
| Product Development Partnerships Hit Their Stride: Lessons From Developing A Meningitis Vaccine For Africa | Q22306071 | ||
| The World Health Organization and the transition from "international" to "global" public health | Q24545557 | ||
| CEREBROSPINAL MENINGITIS IN AFRICA | Q24643970 | ||
| Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa | Q26778266 | ||
| Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials | Q26778276 | ||
| The Evolution of the Meningitis Vaccine Project | Q26778281 | ||
| From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project | Q26778284 | ||
| The impact of new vaccine introduction on immunization and health systems: a review of the published literature | Q27009450 | ||
| How the case against the MMR vaccine was fixed | Q28302493 | ||
| Interactions between Global Health Initiatives and country health systems: the case of a neglected tropical diseases control program in Mali | Q28475151 | ||
| Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso | Q28744396 | ||
| Global health actors claim to support health system strengthening: is this reality or rhetoric? | Q28754757 | ||
| Ten best readings in … the Bamako Initiative | Q29039767 | ||
| Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. | Q30566557 | ||
| Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine | Q34191003 | ||
| The GAVI Alliance and the 'Gates approach' to health system strengthening | Q34201888 | ||
| Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. | Q51004314 | ||
| After flu vaccine mismatch, calls for delayed selection intensify. | Q51035417 | ||
| Ethics in public health research: a research protocol to evaluate the effectiveness of public-private partnerships as a means to improve health and welfare systems worldwide. | Q53215701 | ||
| Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000 | Q56829344 | ||
| Health impact of nanomaterials? | Q57010200 | ||
| Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries | Q73483944 | ||
| Introducing new vaccines into developing countries: obstacles, opportunities and complexities | Q81617022 | ||
| Meningococcal vaccine introduction in Mali through mass campaigns and its impact on the health system. | Q34210674 | ||
| Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data | Q34346578 | ||
| Health systems frameworks in their political context: framing divergent agendas. | Q34413156 | ||
| Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine | Q34430626 | ||
| Revisiting financial conflicts of interest in FDA advisory committees | Q34460311 | ||
| Cuba--innovation through synergy | Q34553193 | ||
| Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14 | Q35064842 | ||
| Global challenges of implementing human papillomavirus vaccines | Q35128768 | ||
| Measuring the health systems impact of disease control programmes: a critical reflection on the WHO building blocks framework | Q35130630 | ||
| Lessons learned during the development and transfer of technology related to a new Hib conjugate vaccine to emerging vaccine manufacturers | Q35187036 | ||
| Human papillomavirus, vaccines and women's health: questions and cautions | Q35944586 | ||
| Clonal groupings in serogroup X Neisseria meningitidis | Q37320175 | ||
| Twenty-first century vaccinomics innovation systems: capacity building in the global South and the role of Product Development Partnerships (PDPs). | Q37898137 | ||
| Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil | Q38051681 | ||
| Global burden of human papillomavirus and related diseases. | Q38064060 | ||
| Institutional corruption of pharmaceuticals and the myth of safe and effective drugs | Q38148604 | ||
| Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews | Q38256986 | ||
| Neoliberal pharmaceutical science and the Chicago School of Economics | Q38389950 | ||
| Capacity for a global vaccine safety system: the perspective of national regulatory authorities. | Q38416020 | ||
| The impact of introducing new vaccines on the health system: case studies from six low- and middle-income countries. | Q38925995 | ||
| New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries. | Q38926004 | ||
| Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project | Q39214102 | ||
| Mass campaigns versus general health services: what have we learnt in 40 years about vertical versus horizontal approaches? | Q39251943 | ||
| Costs and impact of meningitis epidemics for the public health system in Burkina Faso | Q43930276 | ||
| Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo | Q43931792 | ||
| The real cost of an affordable vaccine for meningococcus A. | Q46814777 | ||
| Perspectives on polio and immunization in Northern Nigeria | Q48030959 | ||
| Health interventions and the persistence of rumour: the circulation of sterility stories in African public health campaigns | Q48292751 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | collaboration | Q1145523 |
| meningitis | Q48143 | ||
| P304 | page(s) | 419-32 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Medical Anthropology | Q15759469 |
| P1476 | title | Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project | |
| P478 | volume | 35 |
| Q41224087 | Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968-2000. |
| Q47576810 | Measuring vaccine acceptance among Canadian parents: A survey of the Canadian Immunization Research Network |
| Q64054179 | Strategies to improve maternal vaccination acceptance |
| Q90396484 | Vaccine Development and Collaborations: Lessons from the History of the Meningococcal A Vaccine (1969-73) |
Search more.